Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Early Onset PMR Patients
NCT03632187Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire de Brest
- Start
- Dec 2018
- Primary completion
- Oct 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised trial of abatacept in polymyalgia rheumatica (PMR) (2 arms), sponsored by Centre Hospitalier Universitaire de Brest. Primary endpoint: C-reactive protein at 12 weeks. Started Dec 2018; status: completed.
02
Drugs
abatacept
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NCT03632187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03632187.